At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 685 enrolled
Drug / intervention
Atogepantdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 3, Multicenter, Open-Label 40-week Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Atogepant for the Prevention of Migraine in Participants With Episodic Migraine
In Brief
A Phase 3 clinical trial evaluating Atogepant for Episodic Migraine. Completed, enrolled 685 participants across 113 sites.
Detailed Summary
The purpose of this study is to evaluate the safety and tolerability of atogepant 60 mg once a day for the prevention of migraine in participants with episodic migraine.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsEpisodic Migraine
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2020202120222023202420252026
First PostedMay 2019
Enrollment StartMay 2019
Primary CompletionMar 2021
TodayJul 2026
First PostedMay 6, 2019
Enrollment StartMay 6, 2019
Primary CompletionMar 31, 2021
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 7.2 years ago
Interventions
Atogepantdrug
Atogepant Tablets